Drug Shortage Report for SKYRIZI
| Report ID | 188265 |
| Drug Identification Number | 02487454 |
| Brand name | SKYRIZI |
| Common or Proper name | Risankizumab |
| Company Name | ABBVIE CORPORATION |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RISANKIZUMAB |
| Strength(s) | 90MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 2 x 75 mg/0.83 mL Syringe |
| ATC code | L04AC |
| ATC description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2023-09-01 |
| Actual start date | 2023-09-01 |
| Estimated end date | Unknown |
| Actual end date | 2024-12-16 |
| Shortage status | Resolved |
| Updated date | 2025-01-27 |
| Company comments | SKYRIZI 75mg/0.83 mL (90 mg/mL) pre-filled syringe format is slowly being depleted and is no longer available to order. For several months now, SKYRIZI has been available in two other formats – a 150 mg/1 mL (150 mg/mL) pre-filled pen or a 150 mg/1 mL (150 mg/mL) syringe for order. The decision of discontinuation was made at the end of 2024. AbbVie no longer intends to be meeting demand and this drug will be discontinued. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-01-27 | English | Compare |
| v3 | 2023-09-02 | English | Compare |
| v2 | 2023-03-30 | French | Compare |
| v1 | 2023-03-30 | English | Compare |
Showing 1 to 4 of 4